NeuroSense Therapeutics Ltd.   Report issue

For profit Phase 2
Founded: Herzeliya Israel (2016)

Organization Overview

First Clinical Trial
2019
NCT04090684
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

NeuroSense Therapeutics Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

celecoxib (celebrex) (4 trials)

ciprofloxacin (cipro) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2